Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20089 in platinum-resistant ovarian cancer
NCT06855069Phase 3Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mocertatug rezetecan in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Hansoh Pharmaceutical Group. Started Mar 2025; status: recruiting.
02
Drugs
mocertatug rezetecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06855069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06855069.